Document:

EX-10.27

 Exhibit 10.27 
  

 

         

			
		  	Project no. 838450 /30000 TICK/SAI

  

 Funding contract 

agreed between 

Österreichische Forschungsförderungsgesellschaft mbH (FFG) 

as funding donor 
 and 

ARSANIS Biosciences GmbH 

Helmut-Qualtinger-Gasse 
 2 1030
Vienna 
 Company register number FN 354305m 

as funding recipient. 
 1
Awarding of the funding 
  

					
	1.1    	 	Based on the funding request submitted for the EUROSTARS CoD 8 on cut-off date 3/1/2012 and consequently received in the FFG eCall on 8/31/2012, the “EUROSTARS CoD 8: 7563
KLEBSICURE—development of monoclonal antibody-based immune therapy and diagnostics for severe Klebsiella infections” and based on the professional decision according to the recommendation of the Eurostars decision-making bodies on
6/12/2012, funding is awarded for the following project:
		
		 	 Project number: 8384 50 

Project name (subject of the agreement):

		 		  	EUROSTARS CoD8: 7563 KLEBSICURE - development of monoclonal antibody-based immune therapy and diagnostics for severe Klebsiella infections
		 	Program:	  	EUROSTARS
		 	Tender:	  	Eurostars CoD 8 2012_BMWFJ

  
 ./2 

					
	 Österreichische

Forschungsförderungsgesellschaft mbH
 Sensengasse 1

1090 Vienna
	  	 Tel +43(0)5 7755-0
 Fax+43 (0)5 7755-97900

www.ffg.at, office@ffg.at
 FN 252263a HG Vienna
	  	

 

         

			
	 Page
 2
	  	Project no. 838450 /30000

  

 2 Project duration 

 

	2.1	The overall project duration begins on 8/1/2012 and ends on 1/31/2015. 

 3 Funding period

  

	3.1	The objective funding period of the project begins on 8/1/2012 as acceptance deadline and ends on 1/31/ 2015. 

4 Type and level of funding 
  

	4.1	The funding is provided in the following form for the funding period specified in section 3: 

  

					
	 Funding form
	  	Amount up to max.	 
	 Grant of FFG (Eurostars)
	  	EUR	 1,469, 000.00	 
	 EU bonus top-up (max. 25%)
	  	EUR	 239, 000.00	 
		  	  
	  
	 
	 Total
	  	EUR	 1,708, 000.00	 

 The FFG grant is financed from additional funds provided by the Bundesministerium für Wirtschaft, Familie
und Jugend [Federal Ministry of Economics, Family and Youth] 
 The EU top-up bonus is financed out
of European Commission funds. 
  

	4.2	The subsidized financing of the project amounts to 60.0% of the demonstrable and eligible project costs. The remaining funding of the project costs is the responsibility of the funding recipient. Based on the planning
data, the funding cash value amounts to EUR 1,708,000.00, that is 60.0% related to the eligible costs according to point 5.1. 

  

	4.3	The maximum funding cash value according to the applicable community guidelines for state R&D aid amounts to 60.0%. 

  

	4.4	The consequence of the shortfall of the eligible project costs is an aliquot reduction of the funding. 

  

	4.5	The eligible project costs according to section 5 as well the costs reported through interim and final settlements do not represent any cost acknowledgment before an assessment by the FFG. The final amount of the
eligible total project costs as well as the funding is determined only after completion of the project during invoice verification. 

5 Eligible costs 
  

	5.1	The funding is subject to the following eligible project costs: 

  

					
	 Personnel costs
	  	EUR	 1,662,000.00	 
	 R&D infrastructure use
	  	EUR	 152,743.00	 
	 General and material costs
	  	EUR	 587,257.00	 
	 Third-party services
	  	EUR	 435,000.00	 
	 Travel expenses
	  	EUR	 10,000.00	 
		  	  
	  
	 
	 Total eligible costs
	  	EUR	 2,847,000.00	 

  
 ./3 

					
	 Österreichische

Forschungsförderungsgesellschaft mbH
 Sensengasse 1

1090 Vienna
	  	 Tel +43(0)5 7755-0
 Fax+43 (0)5 7755-97900

www.ffg.at, office@ffg.at
 FN 252263a HG Vienna
	  	

 

         

			
	 Page
 3
	  	Project no. 838450 /30000

  

	5.2	Eligible costs are all those costs and expenses attributable to the project that result directly, actually and additionally from the usual operating costs for the duration of the funded research activity. Additional
supplementary provisions to the eligible costs can arise from FFG guidelines and from the “guidelines for handling project costs in funding applications and reports for funded projects with EU co-funding
(Version 1.3)”. 

  

	5.3	Substantial changes to the cost structure require the prior written approval of the FFG. 

  

	5.4	The sales tax levied on the costs of the service is not eligible. In so far as this sales tax demonstrably and finally is to be borne by the funding recipient and consequently no
pre-tax deduction is applicable for him/her, it is taken into account as an eligible cost component. The—in whatever way—recoverable sales tax is not eligible, if the funding recipient does not get
it back. If the tax office regards a grant not as a taxable service of the funding recipient to the funding donor according to BGBI no. 663 of the 1994 sales tax, but as contractual remuneration and sales tax is thus payable to the tax office by the
funding recipient, the contractual remuneration is to be regarded as gross remuneration. An additional separate sales tax settlement is—for whatever legal reason—excluded. 

 

	5.5	If the amortization period of an item (section 285 ABGB), which is purchased to carry out the project, exceeds the funding period, the depreciation costs are eligible in the manner specified according to the FFG basis
programs guidelines and in the “guidelines for handling the project costs in funding requests and reports (Version 1.3)”. 

  

	5.6	The funding means of the funding donor must not be used for the creation of reserves and provisions according to BGBI no. 400 of the 1988 income tax law. The funding means must be used only for the services and
objectives set out in the funding request. 

  

	5.7	From a temporal point of view, only costs can be recognized as eligible from the project start in accordance with Article 3. 

  

	5.8	The costs incurred by the funding recipient or his/her partners from preparation of the contract, or any transfer charges, must be borne by these parties and do not constitute eligible costs. 

 

	5.9	The funding donor reserves the right to defer, reduce or suspend payment of funding, if and as long as circumstances are such that the orderly execution of the sponsored project appears not to be guaranteed (e.g. the
cost justification is not provided as planned). 

 6 Project-specific conditions and requirements 

 

	6.1	Project-specific special conditions and requirements 

  

	 	1.	Before payment of the 1st installment, the remaining funding must be demonstrated in writing within 12 weeks of the contract issue date. 

 

	 	2.	The upper limit of the hourly rates accounted for in the final settlement are the rates according to BGBl. II no. 50/1999, Annex 3; furthermore, overheads according to “FFG cost guidelines” that arise directly
from the research project can be deducted. 

  
 ./4 

					
	 Österreichische

Forschungsförderungsgesellschaft mbH
 Sensengasse 1

1090 Vienna
	  	 Tel +43(0)5 7755-0
 Fax+43 (0)5 7755-97900

www.ffg.at, office@ffg.at
 FN 252263a HG Vienna
	  	

 

         

			
	 Page
 4
	  	Project no. 838450 /30000

  

 7 Payment of the funding 

 

	7.1	The specified funding amount is transferred in accordance with the following payment plan: 

  

					
	 On contract completion:
	  	€	367,250.00	 
	 after presentation and approval of the 1st interim report and interim settlement on the deadline
6/30/2013
	  	€	367,250.00	 
	 after presentation and approval of the 2nd interim report and interim settlement on the deadline
12/31/2013
	  	€	367,250.00	 
	 after presentation and approval of the 3rd interim report and interim settlement on the deadline
7/31/2014
	  	€	367,250.00	 

 A residual installment of €239,000.00 is subject to the approval of the final report and examination of
the final statement. In the course of the final reporting, fulfillment of the listed conditions must be demonstrated. 
  

	7.2	The transfer is made to the following account of the funding recipient 

  

			
	Account owner:	  	ARSANIS Biosciences GmbH
	Bank name:	  	
	IBAN:	  	
	BIC/SWIFT:	  	

 8 Reporting obligations 
  

	8.1	The funding recipient must report the implementation of the funded project by submitting technical reports (interim and final reports) and settlements to the FFG according to point 3 of the General Funding Conditions.
Reporting and accounting must take place via eCall (https://ecall.ffg.at). Use of the forms defined in eCall is mandatory. Further documents must be made available to the FFG on request. 

 

	8.2	The project coordinator is also obliged to create half-yearly joint reports for the project partners in English and transmit them to the EUREKA secretariat (ESE). 

 

	8.3	The funding recipient is obliged to cooperate fully on any possible assessment or audit of the project together with a designated entity, with an organ of the federation or the EU or EUREKA secretariat or
representatives of the funding organization. This obligation remains valid after the end of the agreement. 

 9 Contract
changes 
  

	9.1	Changes to the current contract can be only made in written form. This applies also to a departure from this provision. 

  

	9.2	Changes that concern the international Eurostars project require approval of the Eurostars decision-making bodies by means of the “Request for Change” procedure. 

  
 ./5 

					
	 Österreichische

Forschungsförderungsgesellschaft mbH
 Sensengasse 1

1090 Vienna
	  	 Tel +43(0)5 7755-0
 Fax+43 (0)5 7755-97900

www.ffg.at, office@ffg.at
 FN 252263a HG Vienna
	  	

 

         

			
	 Page
 5
	  	Project no. 838450 /30000

  

 10 Liability 
  

	10.1	The funding recipient must be liable without limit to the FFG for adherence to all contractual conditions. The funding recipient is also liable for the behavior of third parties for whom he/she is responsible (e.g.
owners, corporate bodies, etc.). The funding recipient indemnifies and holds the FFG harmless against the claims of third parties. 

11 Severability clause 
  

	11.1	If a provision of this funding contract proves ineffective, the effectiveness of the remaining provisions of the funding contract are not affected. The contracting parties undertake to replace an ineffective provision
by a provision that comes closest to the purpose of the contract. 

 12 Applicable law 

 

	12.1	This contract and all its Annexes are subject to Austrian law excluding the reference provisions of the Austrian IPRG [International Private Law Act]. 

13 Jurisdiction 
  

	13.1	The competent court in Vienna has jurisdiction in all litigation arising from the granting of funds. The FFG also retains the right to sue the funding recipient in his/her general jurisdiction. 

14 Contract components 
  

	14.1	The following documents are the integral elements of the funding contract: 

  

	 	•	 	the funding request (“EUROSTARS CoD8: 7563 KLEBSICURE—development of monoclonal antibody-based immune therapy and diagnostics for severe Klebsiella infections”) 

 

	 	•	 	guidelines for handling project costs in funding applications and reports for assisted projects with EU co-financing (version 1.3) 

 

	 	•	 	General funding conditions for funding contracts in the current version (1/26/2009) 

  

	 	•	 	national guidelines for the creation of a Eurostars funding application in the current version 

  

	14.2	The following are regarded as the legal basis of this funding contract: 

  

	 	•	 	Österreichische Forschungsförderungsgesellschaft mbH establishment act (research funding, structure reform act) in the currently applicable version 

 

	 	•	 	the guidelines for the Österreichische Forschungsförderungsgesellschaft mbH for the funding of research, technology, development and innovation (FFG guidelines GZ: BMVIT-609.986/0005-111/12/2008 and BMWA-98.310/0032-C1/10/2008) 

 

  
 ./6 

					
	 Österreichische

Forschungsförderungsgesellschaft mbH
 Sensengasse 1

1090 Vienna
	  	 Tel +43(0)5 7755-0
 Fax+43 (0)5 7755-97900

www.ffg.at, office@ffg.at
 FN 252263a HG Vienna
	  	

 

         

			
	 Page
 6
	  	Project no. 838450 /30000

  

 The funding recipient confirms his/her awareness of all contract components and accepts them without
reservation. 
 The funding recipient also expressly confirms having read the documents “Eurostars Program Document endorsed by the High Level Group
(HLG) in Como on October 19, 2006 and revised according HLG meeting in Venice on April 18-19, 2007”, the relevant “Eurostars Guidelines” and the national “Guidelines for creating a
Eurostars funding application” and accepts to submit fully and without restriction to their contents. 
 By signing this funding contract, the funding
recipient confirms that he/she is not requesting, has not requested, has not been awarded or has not received any other national and/or international funds or community funds for the contractual project. 

It is hereby noted that the objective funding offer must be deemed as revoked, if the funding recipient does not return it signed to the FFG within 3 months.

 For the funding donor: 
 Österreichische
Forschungsförderungsgesellschaft mbH (FFG) 
 [seal:] 

Austrian Research Promotion Agency mbH (FFG) 

Vienna, on 11/28/2012 
  

					
	 /s/ Dr. Henrietta Egerth-Stadlhuber
	 		  	 /s/ Dr. Klaus Pseiner

	 Dr. Henrietta Egerth-Stadlhuber
 Managing
Director
	 		  	 Dr. Klaus Pseiner
 Managing
Director

 Funding recipient 

Vienna                 , on 12/5/2012 

 

					
		 		 	 ARSANIS

Biosciences GmbH
 MarxBox

Helmut-Qualtinger-Gasse 2
 1030
Vienna

	/s/ Dr. Eszter Nagy	 		 
	 (Add company signature, name and position in block letters, company stamp)

 
 Eszter Nagy, MD, PhD

Managing Director
	 		 

  
 ./7 

					
	 Österreichische

Forschungsförderungsgesellschaft mbH
 Sensengasse 1

1090 Vienna
	  	 Tel +43(0)5 7755-0
 Fax+43 (0)5 7755-97900

www.ffg.at, office@ffg.at
 FN 252263a HG Vienna
	  	

 

         

			
	 Page
 7
	  	Project no. 838450 /30000

  

 Attachments: 

General funding conditions for funding contracts in the current version (1/26/2009) 

Guidelines for handling project costs in funding applications and reports for assisted projects with EU co-financing
(version 1.3) 
 Guidelines for the Österreichische Forschungsförderungsgesellschaft mbH for funding of research, technology, development and
innovation (FFG guidelines) as per link: http://www.ffg.at/getdownload.php?id=21Eurostars Guidelines as per link: http://www.eurostars-eureka.eu/ 

National guidelines for the creation of a Eurostars funding application in the current version as per link: 

www.ffg.at/eureka 

  

					
	 Österreichische

Forschungsförderungsgesellschaft mbH
 Sensengasse 1

1090 Vienna
	  	 Tel +43(0)5 7755-0
 Fax+43 (0)5 7755-97900

www.ffg.at, office@ffg.at
 FN 252263a HG ViennaEX-10.28

 Exhibit 10.28 
  

 FFG         

Project no. 840293/30000 SCK/SAI 
  

 Funding Contract 

executed between the 

Österreichische Forschungsförderungsgesellschaft mbH (FFG) 

as Funding Agency 
 and 

ARSANIS Biosciences GmbH 

Helmut-Qualtinger-Gasse 2 
 1030
Vienna 
 Company Register No. 354305m 

as Funding Recipient. 
 §
1 Funding grant 
  

	1.1	On the basis of the funding application “Development of antibody-based therapeutics for the treatment of life-threatening pneumococcal diseases” received 1/31//2013 via eCall, and based on the expert decision
of the Advisory Board in its meeting of 3/20/2013, funding is granted for the following project: 

 Project number: 840293
 
 eCall number: 3595150 

Project name (purpose of the agreement): 

Development of antibody-based therapeutics for the treatment of life-threatening 

pneumococcal diseases 

Program:           Base program 

  
 ./2 

 

					
	 Österreichische

Forschungsförderungsgesellschaft mbH
 Sensengasse

1090 Vienna 
	  	 Phone +43 (0)5 7755 - 0
 Fax+43 (0) 5 7755
-97900
 www.ffg.at, office@ffg.at
 FN 252263a Comm. Court
Vienna
	  	

 FFG         

Project no. 840293/30000 SCK/SAI 
  

 Page 2 

§ 2 Project period 
  

	2.1	The overall project period shall begin on 2/1/2013 and end on 5/31/2017. 

  

	2.2	Funding of the entire project by the FFG depends on the results as demonstrated in the submitted reports, the continued fulfillment of the evaluation and decision criteria, the budget available to the Funding Agency and
a new positive funding decision. 

 § 3 Funding period 

 

	3.1	The funding period of this project shall begin on the approval date 2/1/2013 and end on 1/31/2014. 

§ 4 Type and amount of funding 
  

	4.1	Funding will be awarded in the following form over the funding period specified in § 3: 

  

					
	 Type of funding
	  	Maximum amount	 
	 Subsidy granted by the FFG
	  	 	EUR 770,100.00	 
	 Loan granted by the FFG
	  	 	EUR 630,800.00	 

  

			
	Loan conditions	  	
	Interest rate	  	1.0% p.a. per current account
	Redemption date:	  	6/30/2022
	Redemption amount:	  	EUR 630,800.00
	Interest and loan collection:	  	automatic debit procedure
	Interest payment due:	  	semi-annually in arrears and/or upon maturity of the loan

  

	4.2	The funded financing of the project is 70.0% of the verifiable and eligible project costs. The Funding Recipient shall finance the remaining project costs. Based on the plan data, the cash value of the funding is EUR
900,600.00, i.e. 45.0% related to the eligible project costs pursuant to Point 5.1. 

  

	4.3	The maximum funding cash value according to the applicable Community Framework for public R&D subsidies is 45.0%. 

  

	4.4	A decrease in the eligible project costs shall entail a prorated cutback of the funding. 

  

	4.5	The eligible project costs pursuant to § 5 and the costs reported by way of interim and/or final accounts shall not be considered approved until a review by the FFG. The final amount of the approved overall project
costs as well as the funding shall be determined only after the completion of the project in the course of the final audit. 

  
 ./3 

 

					
	 Österreichische

Forschungsförderungsgesellschaft mbH
 Sensengasse

1090 Vienna
	  	 Phone +43(0)5 7755 - 0
 Fax+43 (0) 5 7755
-97900
 www.ffg.at, office@ffg.at
 FN 252263a Comm. Court
Vienna
	  	

 FFG         

Project no. 840293/30000 
  

 Page 3 

§ 5 Eligible costs 
  

	5.1	The funding is based on following eligible project costs: 

  

									
	 Personnel costs
	  	 	EUR	 	  	 	807,700.00	 
	 Cost of use of R&D infrastructure
	  	 	EUR	 	  	 	49,300.00	 
	 Cost of materials
	  	 	EUR	 	  	 	245,000.00	 
	 Third-party costs
	  	 	EUR	 	  	 	885,000.00	 
	 Travel costs
	  	 	EUR	 	  	 	14,400.00	 
	 Total eligible costs
	  	 	EUR	 	  	 	2,001,400.00	 

  

	5.2	All costs attributable to the project which are incurred directly, actually and additionally to the normal operating expenses during the research activities to § 3 are eligible costs. Additional supplementary
provisions regarding eligible costs may be found in the FFG Guidelines, the FFG Guidelines Base Programs and the “Guide for the Treatment of Project Costs in Funding Applications and Reports”. 

 

	5.3	Major changes to the cost structure shall require the prior written approval of the FFG. 

  

	5.4	The turnover tax payable on the costs of eligible services is not an eligible cost. However, it is considered an eligible cost component if it can be demonstrated that said turnover tax must be borne in actual fact and
without recourse by the Funding Recipient, i.e. if it is not entitled to the input tax deduction. The refundable turnover tax—in whatever way—is not eligible even if it is not actually refunded to the Funding Recipient. If the tax office
considers funds which are taxable under the Turnover Tax Act 1994, Federal Gazette No. 663 not as funding but as a contractual compensation for services provided by the Funding Recipient to the Funding Agency, and if the Funding Recipient owes
turnover tax on such funds to the tax office, the contractual compensation shall be regarded as gross compensation. An additional, separate reimbursement of the turnover tax—for whatever legal reason—shall thus be excluded.

  

	5.5	If the amortization period of an asset (Sec. 285 ABGB [Civil Code]) purchased for the implementation of the project exceeds the funding period, the depreciation costs shall be eligible in the manner described in
the” Guide for Individual Projects of Experimental Development and the “Guide for the Treatment of Project Costs in Funding Applications and Reports”. 

 

	5.6	Funds provided by the Funding Agency may not be used for the creation of reserves or accruals under the Income Tax Act 1988, Federal Gazette No. 400. The funds may be used only for goods and services and for the
purposes described in the funding application. 

  

	5.7	In case of new applications, the eligible costs incurred after receipt of the funding application may be approved. In case of follow-up applications, the earliest date for cost approval shall be the beginning of the
funding period stated under § 3. 

  

	5.8	The costs of drawing up the agreement or the bank transfer expenses incurred by the Funding Recipient or its affiliates shall be borne by them and shall not be eligible costs. 

  
 ./4 

 

					
	 Österreichische

Forschungsförderungsgesellschaft mbH
 Sensengasse

1090 Vienna
	  	 Phone +43(0)5 7755 - 0
 Fax+43 (0) 5 7755
-97900
 www.ffg.at, office@ffg.at
 FN 252263a Comm. Court
Vienna
	  	

 FFG         

Project no. 840293/30000 
  

 Page 4 
  

	5.9	The Funding Agency reserves the right to postpone, cut back or suspend the disbursement of funding if and as long as circumstances prevail which might make it impossible to guarantee the proper execution of the promoted
project (e.g. if the documentary evidence for costs is not adequate). 

 § 6 Project-specific terms and conditions

  

	6.1	Project-specific special terms and conditions 

 None. 

§ 7 Disbursement of the funds 
  

	7.1	The first installment in the amount of 50% of the promised funds will be disbursed after signature of the Funding Contract and fulfillment of the terms and conditions stipulated in § 6. 

The second installment in the amount of 30% will be disbursed after the approval of an interim report and an interim statement in which 50% of
the approved total costs must be documented, as well as after fulfillment of the terms and conditions stipulated in § 6. 
 The final
installment in the amount of 20% of the total promised funds will be disbursed only after fulfillment of all terms and conditions (final account, final reports, etc.) and after the audit and approval of the statement of use (discharge) by the FFG.

  

	7.2	The funds will be transferred to the following account of the Funding Recipient 

 Account
holder:                     ARSANIS Biosciences GmbH 

Name of the bank:                  

IBAN:                       
              
 BIC/SWIFT:
                          

§ 8 Reporting obligations 
  

	8.1	According to Point 3 of the General Funding Terms and Conditions, the Funding Recipient must inform the FFG about the execution of the promoted project by submitting technical reports (interim and final reports) and
billing statements. The reports and billing statements must be submitted via eCall (https://ecall.ffg.at). The use of the forms to be found in eCall is mandatory. Other documents might have to be submitted at the request of the FFG.

 § 9 Amendments 
  

	9.1	Changes to this agreement may be made only explicitly and in writing. This shall apply also to any deviation from this requirement. 

  

	9.2	Under special circumstances changes to the stipulated terms and conditions may, if necessary, be made later by mutual agreement in the form of written addenda if special circumstances are present and after a new
advisory board decision. 

  
 ./5 

 

					
	 Österreichische

Forschungsförderungsgesellschaft mbH
 Sensengasse

1090 Vienna
	  	 Phone +43(0)5 7755 - 0
 Fax+43 (0) 5 7755
-97900
 www.ffg.at, office@ffg.at
 FN 252263a Comm. Court
Vienna
	  	

 FFG         

Project no. 840293/30000 
  

 Page 5 

§ 10 Legal liability 
  

	10.1	The Funding Recipient shall be unconditionally liable to the FFG for compliance with all contractual provisions. The Funding Recipient shall also be liable for the conduct of third parties for which it is responsible
(e.g. owners, corporate officers, etc.). The Funding Recipient must hold the FFG harmless against third parties. 

 §
11 Severability clause 
  

	11.1	In the event that be a provision of this Funding Contract is invalid, such event shall not affect the validity of the remaining provisions of the Funding Contract. The contractual partners undertake to replace an
invalid provision by such provision as comes closest to the purpose of this Funding Contract. 

 § 12 Applicable law

  

	12.1	This agreement and all its attachments shall be governed by Austrian law to the exclusion of the reference norms of the Austrian IPRG. 

§ 13 Legal venue 
  

	13.1	The legal venue agreed upon with regard to all legal disputes arising from the funding grant shall be the materially competent court in Vienna. The FFG reserves the right to take action against the Funding Recipient
also at the latter’s general legal venue. 

 § 14 Integral parts of the contract 

 

	14.1	The following documents are an integral part of the Funding Contract: 

  

	 	•	 	The funding application submitted via eCall (“Development of antibody-based therapeutics for the treatment of life-threatening pneumococcal diseases”) as amended on 3/12/2013 

 

	 	•	 	General terms and conditions for Funding Contracts as amended (1/26/2009) 

  

	 	•	 	FFG Guidelines for Base Programs as amended (3/22/2012) 

  

	 	•	 	Guide for the Treatment of Project Costs in Funding Applications and Reports for Projects with Funding Contracts according to the RTD Directives and the FFG Directives, version 1.3. 

 

	14.2	The legal bases of this Funding Contract are in particular: 

  

	 	•	 	Implementation Act of the Österreichische Forschungsförderungsgesellschaft mbH [Research Promotion Structural Reform Act], as amended 

 

	 	•	 	Guidelines of the Österreichische Forschungsförderungsgesellschaft mbH for promoting research, technology, development and innovation (FFG Guidelines GZ: BMVIT- 609.986/0005-III/12/2008 and
BMWA-98.310/0032-C1/10/2008) 

  
 ./6 

 

					
	 Österreichische

Forschungsförderungsgesellschaft mbH
 Sensengasse

1090 Vienna
	  	 Phone +43(0)5 7755 - 0
 Fax+43 (0) 5 7755
-97900
 www.ffg.at, office@ffg.at
 FN 252263a Comm. Court
Vienna
	  	

 FFG         

Project no. 840293/30000 
  

 Page 6 
 The
Funding Recipient confirms being aware of all contract components and accepts them unconditionally. 
 It is pointed out that this funding offer is
considered revoked if the Funding Recipient does not sign it and return it to the FFG within 3 months. 
 For the Funding Agency: 

Österreichische Forschungsförderungsgesellschaft mbH (FFG) 

[stamp:] Austrian Research Promotion Agency               

Vienna, on 3/25/2013 
  

							
	 /s/ Dr. Henrietta Egerth-Stadlhuber
	  		  	 /s/ /Dr. Klaus Pseiner
	  	
	Dr. Henrietta Egerth-Stadlhuber	  		  	Dr. Klaus Pseiner	  	
	Director	  		  	Director	  	

 Funding Recipient 
  

							
	Vienna, on 3/29/2013	  		  	            ARSANIS	  	
		  		  	            Biosciences GmbH	  	
		  		  	            MarxBox	  	
		  		  	            Helmut-Qualtinger-Gasse 2	  	
		  		  	            1030 Vienna	  	

  

					
	 /s/ Dr. Eszter Nagy
	 	Dr. Eszter Nagy, Director	 	
	(company name, please indicate name and position in block letters, company seal)

 Attachments: 
 Guidelines for the
Österreichische Forschungsförderungsgesellschaft mbH for promoting research, technology, development and innovation (FFG Guidelines) per link https://www.ffg.at/content/foerderrichtlinien 

General terms and conditions for Funding Contracts as amended (1/26/2009) 

FFG Guidelines Base Programs as amended (3/22/2012)
 Guide for the
Treatment of Project Costs in Funding Applications and Reports for Projects with Funding Contracts according to the RTD Directives and the FFG Directives, version 1.3. 

  
 ./7 

 

					
	 Österreichische

Forschungsförderungsgesellschaft mbH
 Sensengasse

1090 Vienna
	  	 Phone +43(0)5 7755 - 0
 Fax+43 (0) 5 7755
-97900
 www.ffg.at, office@ffg.at
 FN 252263a Comm. Court
Vienna
	  	

 FFG         

Project no. 840293/30000 
  

 ARSANIS Biosciences GmbH 

Attn.: Dr. Eszter Nagy 
 Helmut-Qualtinger-Gasse 2 

1030 Vienna 
 Account statement per 12/31/2013 

Project 840293 
 Development of antibody-based therapeutics for
the treatment of life-threatening pneumococcal diseases 
  

					
	 Account no.:
	  	 	18462930	 
	 Fiscal year:
	  	 	2013	 
	 Redemption amount (EUR):
	  	 	530,693.00	 
	 Date of redemption:
	  	 	6/30/2022	 
	 Interest rate:
	  	 	1.00	% 

  

					
		  	Balance per 12/31/2012 (EUR)	  	0.00
			
	Reference dates	  	Description of the transaction	  	Transacted amount (EUR)
			
	4/4/2013	  	840293 DA Installment 1 GP basis	  	-315,400.00
			
	6/3/2013	  	840293 Int. 1.00% per 6/30/13	  	-766.00
			
	7/1/2013	  	840293 Int. 1.00% per 6/30/13	  	766.00
			
	12/2/2013	  	840293 Int. 1.00% per 12/31/13	  	-1,616.00
			
	12/23/2013	  	840293 DA Installment 2 GP basis	  	-189,240.00
			
	12/31/2013	  	840293 Int. 1.00% per 12/31/13	  	1,616.00
			
		  	Debited amount (EUR)	  	507,022.00
			
		  	Deposited amount (EUR)	  	2,382.00
			
		  	Balance per 12/31/2013 (EUR)	  	-504,640.00

  
 ./8 

 

					
	 Österreichische

Forschungsförderungsgesellschaft mbH
 Sensengasse

1090 Vienna
	  	 Phone +43(0)5 7755 - 0
 Fax+43 (0) 5 7755
-97900
 www.ffg.at, office@ffg.at
 FN 252263a Comm. Court
Vienna
	  	

 FFG         

Project no. 840293/30000 
  

 ARSANIS Biosciences GmbH 

Attn.: Dr. Eszter Nagy 
 Helmut-Qualtinger-Gasse 2 

1030 Vienna 
 Account statement per 12/31/2014 

Project 840293 
 Development of antibody-based therapeutics for
the treatment of life-threatening pneumococcal diseases 
  

					
	 Account no.:
	  	 	18462930	 
	 Fiscal year:
	  	 	2014	 
	 Redemption amount (EUR):
	  	 	530,693.00	 
	 Date of redemption:
	  	 	6/30/2022	 
	 Interest rate:
	  	 	1.00	% 

  

					
		  	Balance per 12/31/2013 (EUR)	  	504,640.00
			
	Reference dates	  	Description of the transaction	  	Transacted amount (EUR)
			
	6/2/2014	  	840293 Int. 1.00% per 6/30/14	  	-2,541.00
			
	6/30/2014	  	840293 Int. 1.00% per 6/30/14	  	2,541.00
			
	10/7/2014	  	840293 DA Installment 3	  	-26,053.00
			
	12/1/2014	  	840293 Int. 1.00% per 12/31/14	  	-2,709.00
			
	12/31/2014	  	840293 Int. 1.00% per 12/31/14	  	2,709.00
			
		  	Debited amount (EUR)	  	31,303.00
			
		  	Deposited amount (EUR)	  	5,250.00
			
		  	Balance per 12/31/2014 (EUR)	  	-530,693.00

  
 ./9 

 

					
	 Österreichische

Forschungsförderungsgesellschaft mbH
 Sensengasse

1090 Vienna
	  	 Phone +43(0)5 7755 - 0
 Fax+43 (0) 5 7755
-97900
 www.ffg.at, office@ffg.at
 FN 252263a Comm. Court
Vienna
	  	

 FFG         

Project no. 840293/30000 
  

 ARSANIS Biosciences GmbH 

Attn.: Dr. Eszter Nagy 
 Helmut-Qualtinger-Gasse 2 

1030 Vienna 
 Account statement per 12/31/2015 

Project 840293 
 Development of antibody-based therapeutics for
the treatment of life-threatening pneumococcal diseases 
  

					
	 Account no.:
	  	 	18402930	 
	 Fiscal year:
	  	 	2015	 
	 Redemption amount (EUR):
	  	 	530,693.00	 
	 Date of redemption:
	  	 	6/30/2022	 
	 Interest rate:
	  	 	1.00	% 

  

					
		  	Balance per 12/31/2014 (EUR)	  	-530,693.00
			
	Reference dates	  	Description of the transaction	  	Transacted amount (EUR)
			
	6/1/2015	  	840293 Int. 1.00% per 6/30/15	  	-2,672.00
			
	6/30/2015	  	840293 Int. 1.00% per 6/30/15	  	2,672.00
			
		  	Debited amount (EUR)	  	2,672.00
			
		  	Deposited amount (EUR)	  	2,672.00
			
		  	Balance per 12/31/2015 (EUR)	  	-530,693.00

  
 ./10 

 

					
	 Österreichische

Forschungsförderungsgesellschaft mbH
 Sensengasse

1090 Vienna
	  	 Phone +43(0)5 7755 - 0
 Fax+43 (0) 5 7755
-97900
 www.ffg.at, office@ffg.at
 FN 252263a Comm. Court
Vienna

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00275-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00275-of-00352.parquet"}]]